Open Calls for Input and Feedback
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
difelikefalin (Korsuva)
Therapeutic Area: Chronic kidney disease
Draft recommendations posted for stakeholder feedback: March 16, 2023
End of feedback period: March 31, 2023
Draft Recommendation
deucravacitinib (Sotyktu)
Therapeutic Area: Psoriasis, moderate to severe plaque
Draft recommendations posted for stakeholder feedback: March 16, 2023
End of feedback period: March 31, 2023
Draft Recommendation
mavacamten (Camzyos)
Therapeutic Area: Obstructive hypertrophic cardiomyopathy
Draft recommendations posted for stakeholder feedback: March 16, 2023
End of feedback period: March 31, 2023
Draft Recommendation
Open Calls for Patient and Clinician Input
Emergency Department Overcrowding in Canada: An Update
End of feedback period: September, 2023